US 12,303,509 B2
Compounds for the treatment of BRAF-associated diseases and disorders
Patrick Michael Doerner Barbour, Westminster, CO (US); Tanna Marie Bettendorf, Boulder, CO (US); Dean Russell Kahn, Longmont, CO (US); Alex Andrew Kellum, Boulder, CO (US); Ellen Ruth Laird, Longmont, CO (US); David Austin Moreno, Centennial, CO (US); and Li Ren, Superior, CO (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Jun. 4, 2021, as Appl. No. 17/338,767.
Claims priority of provisional application 63/175,655, filed on Apr. 16, 2021.
Claims priority of provisional application 63/116,204, filed on Nov. 20, 2020.
Claims priority of provisional application 63/036,522, filed on Jun. 9, 2020.
Prior Publication US 2022/0288074 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/517 (2006.01); A61K 31/4184 (2006.01); A61K 31/5377 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07D 239/90 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 471/08 (2006.01); C07D 487/08 (2006.01)
CPC A61K 31/517 (2013.01) [A61K 31/4184 (2013.01); A61K 31/5377 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07D 239/90 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 471/08 (2013.01); C07D 487/08 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A compound which is N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide having the structure:

OG Complex Work Unit Chemistry